| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.14 | 0.05 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.05 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.05 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |